The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! About 1.03M shares traded hands or 22.75% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 22.19% since April 18, 2016 and is uptrending. It has outperformed by 17.76% the S&P500.
The move comes after 9 months negative chart setup for the $1.08 billion company. It was reported on Nov, 18 by Barchart.com. We have $29.45 PT which if reached, will make NASDAQ:AMAG worth $54.00M less.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage
Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Deutsche Bank maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, November 19 with “Hold” rating. The rating was maintained by Jefferies on Thursday, August 11 with “Buy”. Deutsche Bank reinitiated the stock with “Hold” rating in Thursday, September 3 report. As per Wednesday, November 4, the company rating was maintained by Deutsche Bank. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Strong-Buy” rating given on Wednesday, August 19 by Zacks. The rating was maintained by Leerink Swann on Wednesday, May 4 with “Outperform”. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Market Perform” rating given on Wednesday, May 4 by Raymond James. The rating was initiated by Barclays Capital on Thursday, January 21 with “Equal-Weight”. Raymond James initiated the shares of AMAG in a report on Tuesday, September 1 with “Outperform” rating. Needham initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, October 27 with “Buy” rating.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.CombidexÂ®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”
Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.24, from 0.83 in 2016Q1. The ratio increased, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Gotham Asset Management Limited Liability last reported 0.12% of its portfolio in the stock. Piedmont Invest Ltd Liability reported 24 shares or 0% of all its holdings. Bank Of America De owns 95,365 shares or 0% of their US portfolio. The United Kingdom-based Oxford Asset has invested 0.18% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Thrivent For Lutherans has 16,940 shares for 0% of their US portfolio. Putnam Investments accumulated 390,455 shares or 0.02% of the stock. Highbridge Capital Ltd Company reported 37,761 shares or 0.01% of all its holdings. Omers Administration Corp holds 26,800 shares or 0.01% of its portfolio. Guggenheim Cap Ltd Liability Company reported 86,688 shares or 0.01% of all its holdings. Citigroup holds 0% or 8,202 shares in its portfolio. Ameriprise Financial Inc reported 270,405 shares or 0% of all its holdings. State Board Of Administration Of Florida Retirement Sys, a Florida-based fund reported 23,861 shares. Cornerstone Cap Mgmt Holdg Ltd Liability accumulated 0% or 25,000 shares. The Massachusetts-based State Street Corp has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Ironwood Inv Lc accumulated 0.82% or 45,635 shares.
Insider Transactions: Since October 20, 2016, the stock had 0 insider purchases, and 1 insider sale for $122,462 net activity. Krop Julie sold $122,462 worth of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, October 20.
AMAG Company Profile
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.